Treatment with PCSK9 inhibitors reduces the expression of scavenger receptors CD16, CD36 and CD45 in patients with stable coronary artery disease and elevated Lp(a) levels
Atherosclerosis is a chronic inflammatory disease driven by dyslipidemia and activation of immune system. Scavenger receptors CD16+, CD36+ and CD45+ on peripheral blood mononuclear cells (PBMCs) are involved in foam cell formation and endothelial dysfunction, promoting atherosclerosis. Although protein convertase...